The role of haematological parameters in predicting the response to radical chemoradiotherapy in patients with anal squamous cell cancer

1Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 10.3322/caac.21492Open DOISearch in Google Scholar

2van der Zee RP, Richel O, de Vries HJC, Prins JM. The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med 2013; 71: 401-11. PMID: 24127500van der Zee RP Richel O de Vries HJC Prins JM The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med 2013 71 401 11 PMID: 24127500Search in Google Scholar

3Ouhoummane N, Steben M, Coutlée F, Vuong T, Forest P, Rodier C, et al. Squamous anal cancer: patient characteristics and HPV type distribution. Cancer Epidemiol 2013; 37: 807-12. doi: 10.1016/j.canep.2013.09.015Ouhoummane N Steben M Coutlée F Vuong T Forest P Rodier C et al Squamous anal cancer: patient characteristics and HPV type distribution Cancer Epidemiol 2013 37 807 12 10.1016/j.canep.2013.09.015Open DOISearch in Google Scholar

4Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer 1999; 85:1686-93. doi: 10.1002/(sici)1097-0142(19990415)85:8<1686::aid-cncr7>3.0.co;2-7Klas JV Rothenberger DA Wong WD Madoff RD Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes Cancer 1999 851686 93 10.1002/(sici)1097-0142(19990415)85:8<1686::aid-cncr7>3.0.co;2-7Open DOISearch in Google Scholar

5Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000; 342: 792-800. doi: 10.1056/NEJM200003163421107Ryan DP Compton CC Mayer RJ Carcinoma of the anal canal N Engl J Med 2000 342 792 800 10.1056/NEJM200003163421107Open DOISearch in Google Scholar

6Nigro ND, Vaitkevicius VK, Considine BJ. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17: 354-6. doi: 10.1007/BF02586980Nigro ND Vaitkevicius VK Considine BJ Combined therapy for cancer of the anal canal: a preliminary report Dis Colon Rectum 1974 17 354 6 10.1007/BF02586980Open DOISearch in Google Scholar

7Czito BG, Willett CG. Current management of anal canal cancer. Curr Oncol Rep 2009; 11: 186-92. doi: 10.1007/s11912-009-0027-1Czito BG Willett CG Current management of anal canal cancer Curr Oncol Rep 2009 11 186 92 10.1007/s11912-009-0027-1Open DOISearch in Google Scholar

8Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-9. doi: 10.1200/JCO.1997.15.5.2040Bartelink H Roelofsen F Eschwege F Rougier P Bosset JF Gonzalez DG et al Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups J Clin Oncol 1997 15 2040 9 10.1200/JCO.1997.15.5.2040Open DOISearch in Google Scholar

9Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-39. doi: 10.1200/JCO.1996.14.9.2527Flam M John M Pajak TF Petrelli N Myerson R Doggett S et al Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study J Clin Oncol 1996 14 2527 39 10.1200/JCO.1996.14.9.2527Open DOISearch in Google Scholar

10Shridhar R, Shibata D, Chan E, Thomas CR. Anal cancer: current standards in care and recent changes in practice. CA Cancer J Clin 2015; 65: 139-62. doi: 10.3322/caac.21259Shridhar R Shibata D Chan E Thomas CR Anal cancer: current standards in care and recent changes in practice CA Cancer J Clin 2015 65 139 62 10.3322/caac.21259Open DOISearch in Google Scholar

11Hagemans JAW, Blinde SE, Nuyttens JJ, Morshuis WG, Mureau MAM, Rothbarth J, et al. Salvage abdominoperineal resection for squamous cell anal cancer: a 30-year single-institution experience. Ann Surg Oncol 2018; 25: 1970-9. doi: 10.1245/s10434-018-6483-9Hagemans JAW Blinde SE Nuyttens JJ Morshuis WG Mureau MAM Rothbarth J et al Salvage abdominoperineal resection for squamous cell anal cancer: a 30-year single-institution experience Ann Surg Oncol 2018 25 1970 9 10.1245/s10434-018-6483-9Open DOISearch in Google Scholar

12Hagemans JAW. ASO Author reflections: salvage surgery for anal cancer. Ann Surg Oncol 2018; 25: 852-3. doi: 10.1245/s10434-018-7025-1Hagemans JAW ASO Author reflections: salvage surgery for anal cancer Ann Surg Oncol 2018 25 852 3 10.1245/s10434-018-7025-1Open DOISearch in Google Scholar

13Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON 2012; 17: 575-80. PMID: 23033302Jakovljevic K Malisic E Cavic M Krivokuca A Dobricic J Jankovic R KRAS and BRAF mutations in Serbian patients with colorectal cancer J BUON 2012 17 575 80 PMID: 23033302Search in Google Scholar

14Cavic M, Krivokuca A, Boljevic I, Brotto K, Jovanovic K, Tanic M, et al. Pharmacogenetics in cancer therapy ̶ 8 years of experience at the Institute for Oncology and Radiology of Serbia. J BUON 2016; 21: 1287-95. PMID: 27837635Cavic M Krivokuca A Boljevic I Brotto K Jovanovic K Tanic M et al Pharmacogenetics in cancer therapy ̶ 8 years of experience at the Institute for Oncology and Radiology of Serbia J BUON 2016 21 1287 95 PMID: 27837635Search in Google Scholar

15Serup-Hansen E, Linnemann D, Høgdall E, Geertsen PF, Havsteen H. KRAS and BRAF mutations in anal carcinoma. APMIS 2015; 123: 53-9. doi: 10.1111/apm.12306Serup-Hansen E Linnemann D Høgdall E Geertsen PF Havsteen H KRAS and BRAF mutations in anal carcinoma APMIS 2015 123 53 9 10.1111/apm.12306Open DOISearch in Google Scholar

16Brotto K, Malisic E, Cavic M, Krivokuca A, Jankovic R. The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in serbian colorectal cancer patients. Dig Dis Sci 2013; 58: 998-1003. doi: 10.1007/s10620-012-2469-9Brotto K Malisic E Cavic M Krivokuca A Jankovic R The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in serbian colorectal cancer patients Dig Dis Sci 2013 58 998 1003 10.1007/s10620-012-2469-9Open DOISearch in Google Scholar

17Lim F, Glynne-Jones R, Lim F, Glynne-Jones R. Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treat Rev 2011; 37: 520-32. doi: 10.1016/j.ctrv.2011.02.003Lim F Glynne-Jones R Lim F Glynne-Jones R Chemotherapy/chemoradiation in anal cancer: a systematic review Cancer Treat Rev 2011 37 520 32 10.1016/j.ctrv.2011.02.003Open DOISearch in Google Scholar

18Peiffert D, Tournier-Rangeard L, Gérard J-P, Lemanski C, François E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012; 30: 1941-8. doi: 10.1200/JCO.2011.35.4837Peiffert D Tournier-Rangeard L Gérard J-P Lemanski C François E Giovannini M et al Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial J Clin Oncol 2012 30 1941 8 10.1200/JCO.2011.35.4837Open DOISearch in Google Scholar

19Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008; 51: 147-53. doi: 10.1007/s10350-007-9125-zRoohipour R Patil S Goodman KA Minsky BD Wong WD Guillem JG et al Squamous-cell carcinoma of the anal canal: predictors of treatment outcome Dis Colon Rectum 2008 51 147 53 10.1007/s10350-007-9125-zOpen DOISearch in Google Scholar

20Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 2007; 13: 895-900. doi: 10.3748/wjg.v13.i6.895Huang K Haas-Kogan D Weinberg V Krieg R Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal World J Gastroenterol 2007 13 895 900 10.3748/wjg.v13.i6.895Open DOISearch in Google Scholar

21Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys 2011; 80: 712-20. doi: 10.1016/j.ijrobp.2010.02.055Hannoun-Levi JM Ortholan C Resbeut M Teissier E Ronchin P Cowen D et al High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study) Int J Radiat Oncol Biol Phys 2011 80 712 20 10.1016/j.ijrobp.2010.02.055Open DOISearch in Google Scholar

22O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol 2017; 18: 849-51. doi: 10.1016/S1470-2045(17)30438-2O’Sullivan B Brierley J Byrd D Bosman F Kehoe S Kossary C et al The TNM classification of malignant tumours-towards common understanding and reasonable expectations Lancet Oncol 2017 18 849 51 10.1016/S1470-2045(17)30438-2Open DOISearch in Google Scholar

23Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55. PMID: 7165009Oken MM Creech RH Tormey DC Horton J Davis TE McFadden ET et al Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 1982 5 649 55 PMID: 716500910.1097/00000421-198212000-00014Search in Google Scholar

24Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009; 45: 2782-91. doi: 10.1016/j.ejca.2009.06.020Matzinger O Roelofsen F Mineur L Koswig S Van Der Steen-Banasik EM Van Houtte P et al Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014) Eur J Cancer 2009 45 2782 91 10.1016/j.ejca.2009.06.020Open DOISearch in Google Scholar

25Landsberg T, Chavaudra J, Dobbs J, Hanks G, Johansson K-A, Möller T, et al. Report 50. J Int Comm Radiat Units Meas 2016; os26: NP-NP. doi: 10.1093/jicru/os26.1.Report50Landsberg T Chavaudra J Dobbs J Hanks G Johansson K-A Möller T et al Report 50 J Int Comm Radiat Units Meas 2016 os26: NP-NP 10.1093/jicru/os26.1.Report50Open DOISearch in Google Scholar

26Landsberg T, Chavaudra J, Dobbs J, Gerard JP, Hanks G, Horiot JC, et al. Report 62. J Int Comm Radiat Units Meas 2016; os32: NP-NP. doi: 10.1093/jicru/os32.1.Report62Landsberg T Chavaudra J Dobbs J Gerard JP Hanks G Horiot JC et al Report 62 J Int Comm Radiat Units Meas 2016 os32: NP-NP 10.1093/jicru/os32.1.Report62Open DOISearch in Google Scholar

27US Department of Health and Human Services, National Institutes of Health National Cancer Institute 2017. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [cited 2021 Mar 15]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdfUS Department of Health and Human Services, National Institutes of Health National Cancer Institute 2017 Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [cited 2021 Mar 15]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdfSearch in Google Scholar

28Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132-7. doi: 10.1016/j.ejca.2016.03.081Schwartz LH Litière S de Vries E Ford R Gwyther S Mandrekar S et al RECIST 1.1-Update and clarification: from the RECIST committee Eur J Cancer 2016 62 132 7 10.1016/j.ejca.2016.03.081Open DOISearch in Google Scholar

29Lino-Silva LS, Salcedo-Hernández RA, Ruiz-García EB, García-Pérez L, Herrera-Gómez Á. Pre-operative Neutrophils/Lymphocyte Ratio in rectal cancer patients with preoperative chemoradiotherapy. Med Arch (Sarajevo, Bosnia Herzegovina) 2016; 70: 256-60. doi: 10.5455/medarh.2016.70.256-260Lino-Silva LS Salcedo-Hernández RA Ruiz-García EB García-Pérez L Herrera-Gómez Á Pre-operative Neutrophils/Lymphocyte Ratio in rectal cancer patients with preoperative chemoradiotherapy Med Arch (Sarajevo, Bosnia Herzegovina) 2016 70 256 60 10.5455/medarh.2016.70.256-260Open DOISearch in Google Scholar

30Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 2014; 111: 330-9. doi: 10.1016/j.radonc.2014.04.013Glynne-Jones R Nilsson PJ Aschele C Goh V Peiffert D Cervantes A et al Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Radiother Oncol 2014 111 330 9 10.1016/j.radonc.2014.04.013Open DOISearch in Google Scholar

31Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, et al. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 479-85. doi: 10.1016/j.ijrobp.2004.09.060Ortholan C Ramaioli A Peiffert D Lusinchi A Romestaing P Chauveinc L et al Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy Int J Radiat Oncol Biol Phys 2005 62 479 85 10.1016/j.ijrobp.2004.09.060Open DOISearch in Google Scholar

32John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2: 20511. PMID: 9166533John M Pajak T Flam M Hoffman J Markoe A Wolkov H et al Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08 Cancer J Sci Am 1996 2 20511 PMID: 916653310.1016/0360-3016(95)97696-XSearch in Google Scholar

33Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw 2010; 8: 123-9. doi: 10.6004/jnccn.2010.0008Pepek JM Willett CG Czito BG Radiation therapy advances for treatment of anal cancer J Natl Compr Canc Netw 2010 8 123 9 10.6004/jnccn.2010.000820064294Open DOISearch in Google Scholar

34Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 2014; 37: 461-6. doi: 10.1097/COC.0b013e31827e52a3Mitchell MP Abboud M Eng C Beddar AS Krishnan S Delclos ME et al Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity Am J Clin Oncol 2014 37 461 6 10.1097/COC.0b013e31827e52a323466576Open DOISearch in Google Scholar

35Jokic V, Savic-Vujovic K, Spasic J, Stanic N, Marinkovic M, Radosavljevic D, et al. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. Expert Rev Anticancer Ther 2021; 6: 673-9. doi: 10.1080/14737140.2021.1893694Jokic V Savic-Vujovic K Spasic J Stanic N Marinkovic M Radosavljevic D et al Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity Expert Rev Anticancer Ther 2021 6 673 9 10.1080/14737140.2021.189369433606592Open DOISearch in Google Scholar

36Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, et al. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 2013; 33: 3291-4. PMID: 23898094Shibutani M Maeda K Nagahara H Noda E Ohtani H Nishiguchi Y et al A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer Anticancer Res 2013 33 3291 4 PMID: 23898094Search in Google Scholar

37Zhang J, Zhang HY, Li J, Shao XY, Zhang CX. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017; 8: 68837-46. doi: 10.18632/oncotarget.18575Zhang J Zhang HY Li J Shao XY Zhang CX The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis Oncotarget 2017 8 68837 46 10.18632/oncotarget.18575562030028978160Open DOISearch in Google Scholar

38Tanić M, Krivokuća A, Čavić M, Mladenović J, Plesinac Karapandžić V, Beck S, et al. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer. Radiat Oncol 2018; 13: 193. doi: 10.1186/s13014-018-1129-4Tanić M Krivokuća A Čavić M Mladenović J Plesinac Karapandžić V Beck S et al Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer Radiat Oncol 2018 13 193 10.1186/s13014-018-1129-4616782030285791Open DOISearch in Google Scholar

39Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, et al. The Implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists. Int J Radiat Oncol Biol Phys 2019; 105: 698-712. doi: 10.1016/j.ijrobp.2019.07.026Bergom C West CM Higginson DS Abazeed ME Arun B Bentzen SM et al The Implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists Int J Radiat Oncol Biol Phys 2019 105 698 712 10.1016/j.ijrobp.2019.07.02631381960Open DOISearch in Google Scholar